Skip to main content
. 2023 Jun 27;124(2):135–148. doi: 10.1055/s-0043-1769735

Fig. 3.

Fig. 3

The ( A ) effectiveness and ( B ) safety compared between individual NOAC types in AF patients with polypharmacy (≥5 concomitantly used drugs) after IPTW. The weighted number of subjects at risk in the pseudo-population, weighted number of events, weighted event rates per 100 PY, and adjusted HRs with 95% CIs after IPTW are illustrated. aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting; NOAC, non-vitamin K antagonist oral anticoagulant; PY, person-years; Ref, reference category; SE, systemic embolism.